The Gene Targeting Core Facility (GTCF) is a fully established core resource to provide expert services for gene targeting of embryonic stem (ES) cells for the development of mouse models. The primary service orovided by this core is that of taking an investigator's gene targeting vector and producing ES cell lines that can be developed into chimeric mice that transmit the pertinent genomic modification(s) through their germline. Investigators utilizing this core have successfully produced a variety of gene knockouts and mouse models of disease. The GTCF is an integral component of the UAB Transgenic Mouse Facility that collectively provides expert services for not only gene targeting via the GTCF, but also blastocyst micro-injection of targeted ES cell clones or DNA constructs for the production of transgenic mouse models, as well as a host of services related to research with mice (e.g. cryopreservation of embryos, rederivation, etc.). The Transgenic Animal Facility is strategically linked with other core resources at UAB including the CCC Small Animal Imaging Core, Clinical Nutrition Research Center Small Animal Phenotyping Core, Research Animal Pathology Laboratory for phenotype assessment, and a specialized mouse-breeding core (Genetically Engineered Mouse and Marker-Assisted Genetics Core). Overall, we have premier resources to make and characterize mouse models for the Center investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR048311-08
Application #
7918100
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
8
Fiscal Year
2009
Total Cost
$107,038
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Yang, Zhenhua; Shah, Kushani; Busby, Theodore et al. (2018) Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest 128:3605-3618
Hough, Kenneth P; Trevor, Jennifer L; Strenkowski, John G et al. (2018) Exosomal transfer of mitochondria from airway myeloid-derived regulatory cells to T cells. Redox Biol 18:54-64
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Ladowski, Joseph M; Martens, Gregory R; Reyes, Luz M et al. (2018) Examining the Biosynthesis and Xenoantigenicity of Class II Swine Leukocyte Antigen Proteins. J Immunol 200:2957-2964
Hough, Kenneth P; Wilson, Landon S; Trevor, Jennifer L et al. (2018) Unique Lipid Signatures of Extracellular Vesicles from the Airways of Asthmatics. Sci Rep 8:10340
Chou, Chu-Fang; Hsieh, Yu-Hua; Grubbs, Clinton J et al. (2018) The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci 90:343-356
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Ladowski, Joseph M; Reyes, Luz M; Martens, Gregory R et al. (2018) Swine Leukocyte Antigen Class II Is a Xenoantigen. Transplantation 102:249-254

Showing the most recent 10 out of 340 publications